Medical World News® Inside the Practice: CancerNetwork® and Duke Herrell on a Novel Suturing Technique for Transurethral Anastomosis

Video

CancerNetwork® shares its latest investigation into novel practices for rendering surgical management of prostate cancer from experts at Vanderbilt Institute for Surgery and Engineering.

CancerNetwork® analyzed the development of a minuscule robot from investigators at the Vanderbilt Institute for Surgery and Engineering that has the potential to revolutionize surgical procedures for treating prostate cancer. Using a lifelike model, the team demonstrated that the device could remove prostate glands and tissues through the urethra as well as accomplish the difficult step of suturing the bladder to the urethra.

Duke Herrell III, a professor of urology and biomedical and mechanical engineering, providesd key insights into the development of the technology and what it means for the future of prostate cancer maintenance in this episode of Inside the Practice.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content
A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

Tool Combining Genomics, AI May Predict Future Prostate Cancer Recurrence

Roman Fabbricatore
July 23rd 2024
Article

A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

Darolutamide Combo Improves Radiological PFS in Metastatic HSPC

Russ Conroy
July 17th 2024
Article

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

CAR T-Cell Therapy Demonstrates Promising Results for mCRPC

Roman Fabbricatore
June 27th 2024
Article

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.

AI-Assisted Contours Exhibit High Accuracy in Evaluating Prostate Cancer

Roman Fabbricatore
June 20th 2024
Article

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.